TSVT
2Seventy Bio Inc. price
0% Past Week
Market Cap
203.97M
Day’s Range
52W Range
Volume (3M)
1.33M
Price-Earnings Ratio
-0.95
Revenue
147.25M
About 2Seventy Bio Inc.
2seventy bio, Inc. is a cell and gene therapy-based company that researches, develops and commercialises cancer treatments. Incorporated in 2021, the 2seventy bio is headquartered in Cambridge, Massachusetts. The company operates locally in the United States.
2seventy bio was initially part of Bluebird, Inc. As of 4 November 2021, the company is an independent public trading entity. 2seventy bio’s oncology treatment products include idecabtagene vicleucel, ide-cel, or Abecma, and CAR-T cell treatment candidates to target multiple myeloma. The company has a collaboration agreement with Bristol-Myers Squibb Company. 2seventy bio trades under the TSVT ticker on the NASDAQ.
Monitor the TSVT share price by adding this company to your eToro watchlist.
Show MoreNick Leschly, MBA
CEO
425
Employees
2021
Founded
Cambridge, Massachusetts, US
HQ
Upcoming Events
7
NOV
REPORTS
2Seventy Bio Inc. Q3 2023 earnings report is expected to be released before market open
Consensus
Moderate Buy
Price Target
13.50
